microdose schedule for tirzepatide Microdosing chart: complete week-by-week dosing guide Microdosing

Evidence and Prevention Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with comorbidities

Social media, especially platforms like TikTok, contributes to the problem by promoting harmful content that reinforces negative body image and encourages eating disorder behaviors

Its production requires solid-phase peptide synthesis (SPPS), which is expensive, slower to scale and more sensitive to impurity generation

Baird AW, Campion DP, OBrien L, Brayden DJ

Each comorbidity represents a potential therapeutic target where GLP-1 receptor activation provides metabolic advantages beyond appetite suppression